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Background: Bone graft substitute such as calcium sulfate are frequently used as carrier material for local
antimicrobial therapy in orthopedic surgery. This study aimed to assess the systemic absorption and disposition of
tobramycin in patients treated with a tobramycin-laden bone graft substitute (Osteoset® T).
Methods: Nine blood samples were taken from 12 patients over 10 days after Osteoset® T surgical implantation.
Tobramycin concentration was measured by fluorescence polarization. Population pharmacokinetic analysis was
performed using NONMEM to assess the average value and variability (CV) of pharmacokinetic parameters. Bioavailability
(F) was assessed by equating clearance (CL) with creatinine clearance (Cockcroft CLCr). Based on the final model,
simulations with various doses and renal function levels were performed. (ClinicalTrials.gov number, NCT01938417).
Results: The patients were 52 +/− 20 years old, their mean body weight was 73 +/− 17 kg and their mean CLCr
was 119 +/− 55 mL/min. Either 10 g or 20 g Osteoset® T with 4% tobramycin sulfate was implanted in various sites.
Concentration profiles remained low and consistent with absorption rate-limited first-order release, while showing
important variability. With CL equated to CLCr, mean absorption rate constant (ka) was 0.06 h-1, F was 63% or
32% (CV 74%) for 10 and 20 g Osteoset® T respectively, and volume of distribution (V) was 16.6 L (CV 89%).
Simulations predicted sustained high, potentially toxic concentrations with 10 g, 30 g and 50 g Osteoset® T
for CLCr values below 10, 20 and 30 mL/min, respectively.
Conclusions: Osteoset® T does not raise toxicity concerns in subjects without significant renal failure. The
risk/benefit ratio might turn unfavorable in case of severe renal failure, even after standard dose implantation.
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Since the end of the sixties, bone cement such as poly-
methyl methacrylate (PMMA) and bone graft substitute
such as calcium sulfate are frequently used as carrier
material for local antimicrobial therapy in orthopedic
surgery for osteomyelitis, infected arthroplasty, soft tissue
infections or prophylaxis. Unlike PMMA, calcium sulfate
is resorbable, thus obviating the need for surgical removal.
Osteoset® T (Wright Medical Technology Inc, Arlington,
TN, USA) is one of these products; it contains 4% tobra-
mycin sulfate in calcium sulfate pellets. Most data on
Osteoset® T come from animal studies, where high local
and low systemic tobramycin concentrations have been
observed [1]. No pharmacokinetic (PK) observations with* Correspondence: francoise.livio@chuv.ch
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reproduction in any medium, provided the orpatients treated with Osteoset® T have been published
so far, despite well known concentration-related potential
toxicity of aminoglycosides. Only concentrations have
been described in patients implanted with a tobramycin-
laden polymer carrier material (Simplex™ P Bone Cement
with Tobramycin) showing high tobramycin levels at the
operative site but low systemic absorption [2].
The aim of this study was to develop a population PK
model for tobramycin in patients treated with an active
calcium sulfate bone substitute and to predict tobra-
mycin systemic exposure under various dose and renal
function levels.Method
Patients and sampling
The data were collected prospectively between October
2006 and March 2008 from all adult patients treated withd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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set® T was implanted whenever estimated a useful adjunct
to standard therapy for bone, soft tissues and prosthetic
joint infections requiring surgical debridement. Either
10 g or 20 g of Osteoset® T with 4% tobramycin sulfate
were implanted, representing 262 or 524 mg tobramycin
repectively taking into account the salt factor (tobra-
mycin/tobramycin sulfate = 0.655). Additional intravenous
aminoglycosides were not used in these patients. No
wound drains were used.
Blood samples were taken at 3 h, 6 h, 12 h, 24 h, 48 h
and on days 3, 5, 7 and 10 after implantation. Whenever
a tourniquet had been used during the operation, its
release-time was taken into account instead of implant-
ation time. Blood was sampled in BD Vacutainer® SST II
Advance (Becton Dickinson AG, Allschwil, Switzerland)
serum separator tubes.
The study protocol was approved by the Institutional
Review Board of Fribourg Cantonal Hospital and all sub-
jects gave their written informed consent. This study
was registered in ClinicalTrials.gov under code number
NCT01938417.
Drug assay
Tobramycin concentrations were measured on a COBAS
INTEGRA 800 (Roche Diagnostics GmbH, Mannheim,
Germany) fluorescence polarization detector, using a
standard tobramycin measurement kit (ref. 20737925).
The lower limit of quantification (LOQ) of the assay
was 0.1 mg/L. Coefficient of variation (CV) within runs
was 1.7% at 2.2 mg/L, while CV between runs were
6.2%, 2.6% and 2.5% at 0.9 mg/L, 2.8 mg/L and 4.5 mg/L,
respectively. Accuracy was monthly checked by participat-
ing to the external quality control scheme provided by
LGC Standards for antibiotics (LGC Standards Proficiency
Testing, Bury, UK). Assays were processed within 6 hours
after sampling.
Population pharmacokinetic analysis
The pharmacokinetic analysis was performed using non-
linear mixed-effects modeling with the NONMEM com-
puter program (version VI) [3]. Models were fitted to
the data with the first-order conditional estimation with
interaction (FOCE INTER) method. One and two com-
partment models with first-order absorption were com-
pared. The first tobramycin concentration below the LOQ
was set to half of the LOQ value and subsequent points
below the LOQ were dropped out. Average value and
variability of clearance (CL), volume of distribution (V)
and absorption rate constant (ka) were assessed. As ami-
noglycosides are known to be completely and exclusively
eliminated by glomerular filtration, tobramycin CL was
equated to the creatinine clearance (CLcr) value, thus
enabling the estimation of absolute bioavailability (F) inthe absence of intravenous injection. CLcr was estimated
with the Cockcroft formula, based on patient’s serum cre-
atinine, body weight, and sex [4], with linear interpolation
for days without creatinine measurement. The residual
variability was adequately modeled using an additive plus
proportional error model. The final model was then devel-
oped by testing in a stepwise fashion the potential influ-
ence of sex, age, body weight, Osteoset® T quantity and
implantation site on the pharmacokinetic parameters.
Based on the final average parameters and variability,
simulations using various tobramycin doses (262 mg;
786 mg; 1310 mg) at various CLcr levels (120, 90, 60, 30,
20 and 10 mL/min) were performed, using 2000 virtual
patients each to predict the doses associated with concen-
trations exceeding the 2 mg/L threshold over a prolonged
period of time (5 days or more).Results
Twelve patients (7 males, 5 females) were included in this
observational study. Their mean age was 52 years (range
19–82, SD ± 20), body weight 73 kg (53–116, ± 17), and
CLcr 119 mL/min (34–288, ± 55).
Osteoset® T implantation sites were tibia/fibula (6 pa-
tients), hip (2), calcaneum (2), femur (1) and lumbar spine
(1), either for established infections (9) or prophylaxis (3).
Eight patients were implanted 10 g Osteoset® T containing
262 mg tobramycin, while 4 were implanted 20 g Osteo-
set® T containing 524 mg tobramycin.
Osteoset® T was well tolerated; further clinical details
have been presented elsewhere [5]. Systemic tobramycin
concentrations measured remained low (<2 mg/L at 24 h)
in all patients. Concentration profiles were consistent with
a one compartement model with absorption rate-limited
first-order release, while showing important variability.
A two compartment model was also tested but did not
improve the fit. With CL equated to CLCr, mean estimated
ka was 0.0603 h
−1, volume of distribution 16.6 L (CV 89%)
and F was 63% and 32% (CV 74%) in the 8 patients having
received 10 g Osteoset® T and in the 4 patients having
received 20 g, respectively. Sex, age, body weight or
implantation site did not seem to affect tobramycin
absorption or disposition when introduced as covariates.
Population pharmacokinetic parameter estimates and
variability are summarized in Table 1. The concentration
values observed are represented on Figure 1, along with
mean population prediction and 90% prediction inter-
vals for CLCr 120 mL/min.
The simulations of concentration profiles (using an aver-
age F estimate of 47%) showed that more than 5% patients
would maintain concentrations over 2 mg/L during at
least five days post implantation with tobramycin 262, 786
and 1310 mg when CLcr was respectively set at 10, 20 and
30 mL/min.
Table 1 Tobramycin population pharmacokinetic
parameter estimates
Population mean
Parameter Estimate s.e%b
CL (L h−1) 7.14d –
V (L) 16.6 35
Ka (h
-1) 0.0603 19
F (if cast 10 g) 0.63 19
F (if cast 20 g) 0.32 19
Interpatient variability
Parameter CV%a s.e%c
CL – –
V 89 74
ka – –
F 74 72
Residual variability
Error type s.e%
σprop (CV%)e 29 50c
σadd (SD in mg/L)f 0.062 22b
CL, mean apparent clearance; V, mean apparent volume of distribution;
ka, mean absorption rate constant; F, mean bioavailability.
aestimates of variability expressed as coefficient of variation (CV%).
bs.e = standard error of the estimates (S.E), defined as S.E/estimate and
expressed as percentage.
cs.e = standard error of the coefficient of variations, taken asﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s:eestimate=estimate
p
, expressed as a percentage.
dequated to creatinine clearance (CLcr).
eresidual variability in the plasma concentrations associated with the
proportional error term, expressed as a coefficient of variation (CV%).
fresidual variability in the plasma concentrations associated with the additive
error term, expressed as a standard deviation (SD).
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This is the first tobramycin pharmacokinetic study after
Osteoset® T implantation in a clinical setting. Tobramycin
systemic concentration values were measured well below
the traditional toxicity threshold of 2 mg/L from 24 h0 24 48 72 96 120 144 168
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Figure 1 Concentrations versus time plot of tobramycin with mean p
(dashed lines) after Osteoset® 10 g (left) or 20 g (right) in patients wi
by different bioavailability, giving similar predictions. Superimposed points sho
after 20 g. v : first concentration below the limit of detection.and later on, which was not unexpected considering
the low tobramycin dose implanted and the good renal
function of the study subjects. Whether continuous sys-
temic exposure to low concentrations below minimal
inhibitory concentration may favor antimicrobial resistance
remains an issue [6].
Prominent inter-individual variability was observed, prob-
ably due to heterogeneity of patients, indications, surgical
techniques and implantation sites. There have probably
been too few patients included for reliably testing the influ-
ence of all covariates. Loss through wound oozing has been
neglected (not measured) but could represent another
source of variability. Imprecision on low tobramycin
levels measurement, very close to the LOQ, could also
have increased residual variability.
The significant difference in bioavailability between 10 g
and 20 g Osteoset® T (63% versus 32% respectively) could
indicate that higher amounts of bone graft substitute
either limit tobramycin release to some extent, or slow
it down sufficiently for the resulting concentrations to
fall below the LOQ. Unbalanced loss through wound
oozing could also partly account for this difference. Im-
plantation site and tissue perfusion could also play a
role, although this could not be demonstrated in our
analysis, due to limited data.
Our model gained in credibility when tobramycin CL
was equated to CLcr; indeed there is no argument to
think of a different elimination route for the drug absorbed
from Osteoset® T compared to intravenous delivery [7]. The
Cockcroft equation that we used has yet its limitations, in
particular in obese or bedridden patients. Our model found
a distribution volume of 0.22 L/kg body weight, consistent
with previously published values [7]. The large inter-patient
variability found in both V and F is likely to incorporate
some amount of variability in CL and ka.
High sustained potentially toxic concentrations were
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opulation prediction (solid line) and 90% prediction interval
th normal renal function. Dose difference is almost fully compensated
w the concentrations observed in 8 patients after 10 g and 4 patients
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study power, this simulation should be taken as a rough
estimate of the potential for toxicity of this product. Our
model is probably too imprecise to deduce precise dose
adjustment guidelines. However, it indicates that caution
is warranted when Osteoset® T implant is considered for
patients with severe renal failure, as its benefit/risk ratio
could turn out unfavourable [8].
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